China’s National Medical Products Administration (NMPA) has approved Zeiss Medical Technology’s retinal imaging system, the ...

Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung fibrosis, marking progress for a disease that kills many patients within ...

China, Germany, Italy and Japan. The company does not do direct to consumer advertising outside the U.S. While OMD leads the account, Boehringer Ingelheim will also utilize other Omnicom ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

The global veterinary dermatology market, valued at US$18.59 billion in 2024, is forecasted to grow at a robust CAGR of 8.5%, ...

Cardiovascular disease and mental illness commonly co-occur. Addressing them together can improve both mental health and ...

The global canine arthritis treatment market stands at a valuation of USD 2.50 billion in 2024. Global demand for canine arthritis treatment medications is predicted to rise at a CAGR of 4.20% and ...

The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...